How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?

Digestive Diseases

Volumn 30, Issue 4, 2012, Pages 396-399

  Rutgeerts, Paul ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Algorithmic approach; Bowel healing; Patient tailored therapies

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ALGORITHM; ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE CONTROL; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; STEROID THERAPY; TREATMENT PLANNING; ULCERATIVE COLITIS;

ANIMALS; DECISION SUPPORT SYSTEMS, CLINICAL; ENDOSCOPY; HUMANS; INDIVIDUALIZED MEDICINE; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84863923285     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000338137     Document Type: Article

References (10)

1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782.
2. Arnott ID, Watts D, Ghosh S: Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002; 16: 857-867.
3. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
4. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes: Predictors of Crohn's disease. J Gastroenterology 2006; 130: 650-656.
5. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R: Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-953.
6. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422.
7. Mary JY, Modigliani R: Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-989.
8. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P: Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-512.
9. Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, Ballet V, Noman M, Hoffman I, van Assche G, Rutgeerts PJ, van Steen K, Vermeire S: Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421-427.
10. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P. De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-1619.